EN DE

PharmaEssentia Corporation (6446) Fair Value & Analysis

Healthcare · TW · Market cap 530B TWD

PC PharmaEssentia Corporation 6446 · TW
Price1,500 TWD
Fair Value233.93 TWD
Upside-84.4%
Quality64/100
Watch PharmaEssentia Corporation for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Highly profitable · 33.9% net margin
Low debt · generates free cash flow
0.06% dividend yield
Mixed vs. peers (7/14)
Wide moat 79/100
Evidence: High Range 188.71 TWD – 546.08 TWD Share as image

Fair value as of: Aug 13, 2026

From 26 valuation models · updated yesterday

Fair value updated Aug 13, 2026, revised from 221.01 TWD to 233.93 TWD (+5.8%) since Jul 11, 2026. Share price +13.6% over the past month.

A solid business, but screening 84% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (546.08 TWD). The favourable scenario is already priced in.
  • The model range is unusually wide (188.71 TWD to 546.08 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution.
  • Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

86,833 TWD 56.21 TWD Fair Value 233.93 TWD Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 56.21 TWD – 86,833 TWD · fair‑value band 188.71 TWD – 546.08 TWD · the 1,500 TWD price screens above the 233.93 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

PharmaEssentia Corporation (6446) currently trades at 1,500 TWD, while our model-based Fair Value estimate is 233.93 TWD, implying the stock looks roughly 84.4% overvalued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, PharmaEssentia Corporation generated revenue of 17.5B TWD at a net margin of 33.9%. Revenue grew 57.2% year over year. It earns a return on equity of 18.7%. The balance sheet holds a net cash position of 21.9B TWD. Fundamentals as of Aug 13, 2026

Our scenario range runs from 188.71 TWD (bear case) to 546.08 TWD (bull case); at 1,500 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades near its 52-week high and 240% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -40% fair-value upside, at -84%, 6446 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely (15.28 TWD to 580.37 TWD). Read the values as a conservative anchor, not as a price target.
Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 192.71 TWD 342.02 TWD 592.77 TWD 80
Residual Income 85.60 TWD 119.35 TWD 507.46 TWD 76
Rev-Margin DCF 169.86 TWD 259.12 TWD 446.06 TWD 74
All 26 models by family
DCF Models
FCF DCF 201.11 TWD 290.60 TWD 583.18 TWD 38
Owner Earnings 197.59 TWD 389.09 TWD 809.11 TWD 31
5Y Revenue Exit 159.13 TWD 233.39 TWD 388.69 TWD 39
5Y EBITDA Exit 198.02 TWD 312.07 TWD 535.89 TWD 41
5Y P/E Exit 249.21 TWD 508.33 TWD 864.83 TWD 38
10Y Revenue Exit 169.33 TWD 302.41 TWD 385.80 TWD 36
10Y EBITDA Exit 202.14 TWD 388.14 TWD 714.09 TWD 37
10Y P/E Exit 240.35 TWD 500.96 TWD 937.53 TWD 35
Earnings-Based
Graham-Dodd 83.22 TWD 580.37 TWD 814.47 TWD 54
Lynch FV 299.84 TWD 428.34 TWD 556.85 TWD 50
PEG = 1.0 299.84 TWD 428.34 TWD 556.85 TWD 46
EPV 162.59 TWD 181.58 TWD 198.45 TWD 59
Dividend Discount
Gordon GGM 8.54 TWD 18.65 TWD 31.38 TWD 70
DDM Multi-Stage 8.54 TWD 15.28 TWD 19.44 TWD 61
Multiples
P/E Multiple 201.93 TWD 269.24 TWD 336.56 TWD 63
P/S Multiple 99.56 TWD 132.74 TWD 165.93 TWD 58
P/B Multiple 156.04 TWD 208.05 TWD 260.07 TWD 55
EV/EBIT 207.42 TWD 258.23 TWD 309.04 TWD 53
EV/EBITDA 190.67 TWD 235.90 TWD 281.13 TWD 54
EV/Revenue 134.64 TWD 168.78 TWD 202.91 TWD 43
Asset-Based
NCAV (Graham) 38.78 TWD 51.97 TWD 77.56 TWD 50
Growth DCF
Growth DCF 192.71 TWD 342.02 TWD 592.77 TWD 80
Rev-Margin DCF 169.86 TWD 259.12 TWD 446.06 TWD 74
Economic Profit
Residual Income 85.60 TWD 119.35 TWD 507.46 TWD 76
ROIC Compounder 192.31 TWD 263.99 TWD 361.46 TWD 72
Growth Earnings
Growth-Adj P/E 398.02 TWD 568.60 TWD 739.18 TWD 68

Widest divergence: Growth Earnings (568.60 TWD) versus Dividend Discount (15.28 TWD). Highest evidence: Growth DCF (80).

Notify me when 6446 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 17.5B TWD
Revenue growth (YoY) +57.2%
Net margin 33.9%
Return on equity 18.7%
Free cash flow 3.4B TWD FY2025
P/E ratio 110.4
More key figures
Operating margin 40.8%
EPS (TTM) 13.59 TWD
Dividend yield 0.1%
EPS growth (YoY) +69.5%
Net cash 21.9B TWD FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 64/100

Of which business quality 66 · Market factors (momentum, volatility) 76

Profitability 66
Margins and returns on capital today
Quality Growth 76
Are margins and returns improving?
Cashflow 68
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 14
Disciplined investing over empire-building
Low Volatility 48
Calm price path (market factor)
Momentum 100
Price trend over the last 3–12 months (market factor)
52W Momentum 67
Distance to the 52-week high (market factor)
Net Issuance 43
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan.

Full company description

PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

PharmaEssentia Corporation reported revenue of 15.6B TWD in FY2025 versus 657M TWD in FY2021, a compound +120.9%/yr. Reported net income was 5.0B TWD in FY2025.

Growth Quality 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
15.6B TWD
Latest YoY
+60.6%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+75.7%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+94.8%
Avg. growth/yr (15Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+46.1%
Revenue +120.9%/yr
FY21 657M TWD
FY22 2.9B TWD
FY23 5.1B TWD
FY24 9.7B TWD
FY25 15.6B TWD
Net income
FY21 −2.8B TWD
FY22 −1.4B TWD
FY23 −624M TWD
FY24 3.0B TWD
FY25 5.0B TWD

6446 screens 84% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PharmaEssentia Corporation · Fair Value
233.93 TWD −84%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "PharmaEssentia Corporation Fair Value". https://www.fairvalue-calculator.com/stock/6446

Earlier news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

Peer Group

Drug Manufacturers - Specialty & Generic · 625 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 64 · Top 25%
Fair Value upside −84% · Bottom 25%
Return on equity (TTM) 19% · Top 25%
Return on assets 10% · Top 25%
Net margin (TTM) 34% · Top 25%
Operating margin (TTM) 41% · Top 25%
Revenue growth 57% · Top 25%
Dividend yield (TTM) 0.1% · Bottom 25%
Debt / equity 0.00× · Lower than 75% of peers

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 110.4× · Pricier than 75% of peers
P/B 16.57× · Pricier than 75% of peers
P/S (TTM) 30.27× · Pricier than 75% of peers
P/FCF 4.9× · Pricier than median
EV/EBITDA 83.6× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 5
FUTURE 100 · sector 21
PAST 75 · sector 25
HEALTH 100 · sector 97
DIVIDEND 1 · sector 34

VALUE 0: the price sits above our fair-value range.

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥53.76 ¥25.94 -52%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,944 ₹989.50 -49%
Divi's Laboratories Limited DIVISLAB ₹8,500 ₹1,932 -77%
Torrent Pharmaceuticals Limited TORNTPHARM ₹4,915 ₹1,163 -76%
Cipla Limited CIPLA ₹1,463 ₹1,001 -32%
Zydus Lifesciences Limited ZYDUSLIFE ₹1,167 ₹703.32 -40%
Lupin Limited LUPIN ₹2,281 ₹2,477 +9%
Mankind Pharma Limited MANKIND ₹2,433 ₹983.11 -60%
Dr. Reddy's Laboratories Limited DRREDDY ₹1,200 ₹874.79 -27%
Aurobindo Pharma Limited AUROPHARMA ₹1,667 ₹1,340 -20%

Compare PharmaEssentia Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is PharmaEssentia Corporation (6446) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 233.93 TWD versus a price of 1,500 TWD, about −84% (overvalued).
What is the fair value of 6446?
Our model-based fair value for PharmaEssentia Corporation is 233.93 TWD (as of Aug 13, 2026), built from audited fundamentals. The current price is 1,500 TWD.
What is the quality score of 6446?
PharmaEssentia Corporation has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of PharmaEssentia Corporation (6446)?
PharmaEssentia Corporation reported trailing-twelve-month revenue of about 17.5B TWD (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 6446?
The net profit margin of PharmaEssentia Corporation is about 33.9%, meaning it keeps roughly 33.9% of revenue as net income. Based on the latest reported figures.
Does PharmaEssentia Corporation pay a dividend?
PharmaEssentia Corporation currently shows a dividend yield of about 0.12% relative to its recent price (as of Aug 13, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track PharmaEssentia Corporation and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.